Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

India Lifts Export Restrictions

Clarifies Ongoing Measures On Paracetamol And Hydroxychloroquine

Executive Summary

India has removed export restrictions on APIs and formulations imposed by the country in March. However, certain measures have been kept in place to ensure that domestic requirements are met for in-demand products such as hydroxychloroquine and paracetamol.

You may also be interested in...



EU Industry Wants End To Isolated National Measures On Coronavirus

A host of European pharmaceutical industry associations, including off-patent body Medicines for Europe, has urged EU trade ministers to push back against European and global restrictions on the movement of medicines and medical equipment that are hampering the international supply chain's response to the coronavirus pandemic.

EU Industry Wants End To Isolated National Measures On Coronavirus

A host of European pharmaceutical industry associations, including off-patent body Medicines for Europe, has urged EU trade ministers to push back against European and global restrictions on the movement of medicines and medical equipment that are hampering the international supply chain's response to the coronavirus pandemic.

Indian Industry Gets HCQ, Paracetamol Exports Rolling

Indian manufacturers hope increased production of hydroxychloroquine and paracetamol, along with emergence of reliable COVID-19 therapies, will lead to export restrictions on these two medicines being removed soon. Meanwhile, they are fulfilling orders routed through the government.

Related Content

Topics

UsernamePublicRestriction

Register

OM017301

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel